Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 USD | -1.54% | -5.88% | -20.00% |
Financials (USD)
Sales 2024 * | 1.1B | Sales 2025 * | 1.13B | Capitalization | 101M |
---|---|---|---|---|---|
Net income 2024 * | -83M | Net income 2025 * | 66M | EV / Sales 2024 * | 0.23 x |
Net Debt 2024 * | 156M | Net Debt 2025 * | 402M | EV / Sales 2025 * | 0.45 x |
P/E ratio 2024 * |
-1.19
x | P/E ratio 2025 * |
1.32
x | Employees | 1,600 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.65% |
Latest transcript on Emergent BioSolutions Inc.
1 day | -1.54% | ||
1 week | -5.88% | ||
Current month | -24.11% | ||
1 month | -24.11% | ||
3 months | +5.49% | ||
6 months | -4.00% | ||
Current year | -20.00% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Papa
CEO | Chief Executive Officer | 68 | Feb. 20 |
Richard Lindahl
DFI | Director of Finance/CFO | 70 | 18-03-25 |
Kelly Warfield
CTO | Chief Tech/Sci/R&D Officer | - | 23-03-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
BRD | Director/Board Member | 52 | 22-03-31 |
Marvin White
BRD | Director/Board Member | 62 | 10-05-31 |
Louis Sullivan
BRD | Director/Board Member | 90 | 04-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.23% | 27 M€ | -5.03% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.92 | -1.54% | 880,929 |
24-04-25 | 1.95 | -10.55% | 1,093,229 |
24-04-24 | 2.18 | -4.80% | 799,932 |
24-04-23 | 2.29 | +6.02% | 860,992 |
24-04-22 | 2.16 | +5.88% | 1,393,297 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.00% | 101M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- EBS Stock